|Day Low/High||38.02 / 38.94|
|52 Wk Low/High||4.67 / 25.07|
Venture Capital firm Benchmark reiterated its 'Buy' rating on the stock and $50 price target.
The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 2,463,634 share decrease in total short interest for EXACT Sciences Corp. , to 22,030,168, a decrease of 10.06% since 05/31/2017.
Golfer launches multi-year, Cologuard®-branded campaign
The secondary offering, to be underwritten by Jefferies, Bank of America/Merrill Lynch and Robert W. Baird, would offer 7 million shares.
Plus more from the biotechnology world on Wednesday, June 7.
Kevin Conroy, chairman, president and CEO at Exact Sciences, tells Jim Cramer about his company's non-invasive test for colon cancer.
Jim Cramer has the game plan for next week, including earnings from Thor Industries and HD Supply.
Jim Cramer focuses on Blackberry, Exact Sciences, Splunk, Freeport-McMoRan and more.
Jim Cramer says it's more than just the cloud. There are some astounding moves in the broader tech sector, too.
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Exact Sciences Corporation ("Exact" or the "Company") (Nasdaq: EXAS).
Apple CEO says fund will boost advanced manufacturing in U.S.
A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
Aetna now offers commercial coverage of Exact Sciences' Cologuard test.
Jim Cramer is bullish on Arconic, Treehouse Foods, Magellan Midstream Partners.
Jim Cramer says if Trump really wants to lower drug prices, he should target our trading partners.
AACR abstract highlights methylation markers capable of detecting all types of lung cancer with more than 90% sensitivity and specificity
Jim Cramer is bullish on T-Mobile, Box and Treehouse Foods. He's bearish on Verizon and Best Buy.